Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials

American Journal of Hematology

Volumn 91, Issue 2, 2016, Pages 199-204

  Castillo, Jorge J ^a   Mulkey, Flora ^b   Geyer, Susan ^c   Kolitz, Jonathan E ^d   Blum, William ^e   Powell, Bayard L ^f   George, Stephen L ^b   Larson, Richard A ^g   Stone, Richard M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d North Shore Long Island Center for Advanced Medicine   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f WAKE FOREST BAPTIST HEALTH   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; BODY MASS; BODY SURFACE; CLINICAL TRIAL (TOPIC); COMPLICATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; OBESITY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY SURFACE AREA; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; TREATMENT OUTCOME;

EID: 84956645738     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24230     Document Type: Article

References (31)

1. Surveillance, Epidemiology, and End Results [website]. SEER Stat Fact Sheets. Available at: http://seer.cancer.gov/statfacts/html/amyl.html. Accessed on November 9, 2015.
2. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113:4179-4187.
3. Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957; 159:189-194.
4. Lo-Coco F, Orlando SM, Platzbecker U. Treatment of acute promyelocytic leukemia. N Engl J Med 2013; 369:1472.
5. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood 2002; 99:759-767.
6. Castillo JJ, Reagan JL, Ingham RR, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: A meta-analysis of prospective cohort studies. Leuk Res 2012; 36:868-875.
7. Estey E, Thall P, Kantarjian H, et al. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997; 11:1661-1664.
8. Medeiros BC, Othus M, Estey EH, et al. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica 2012; 97:1401-1404.
9. Wenzell CM, Gallagher EM, Earl M, et al. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am J Hematol 2013; 88:906-909.
10. Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood 2012; 119:49-54.
11. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004; 22:4290-4301.
12. Blum W, Sanford B, Klisovic RB et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia (AML) in first remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). ASH Annu Meet Abstr 2012;120:44.
13. Kolitz JE, George SL, Benson DM, J, et al. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808. Cancer 2014; 120:1010-1017.
14. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116:3751-3757.
15. Eknoyan G. Adolphe Quetelet (1796-1874) - The average man and indices of obesity. Nephrol Dial Transplant 2008; 23:47-51.
16. World Health Organization. Obesity and Overweight [website]. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed on November 9, 2015.
17. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood 2004; 103:1237-1243.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn 1958; 53:457-481.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
20. Cox DR. Regression Models and Life-Tables. J R Stat Soc Ser B 1972; 34:187-220.
21. Jeddi R, Ghedira H, Mnif S, et al. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res 2010; 34:545-547.
22. Leblebjian H, DeAngelo DJ, Skirvin JA, et al. Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res 2013; 37:747-751.
23. Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: A meta-analysis of cohort studies. Int J Cancer 2008; 122:1418-1421.
24. Mazzarella L, Durfort T, Pelicci PG. Modelling the influence of diet on APL identifies Insulin-Growth Factor 1 as a central mediator and provides a mechanistic rationale for therapeutic weight loss. Blood (ASH Annu Meet Abstr) 2013;Abstract 833.
25. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307:491-497.
26. De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998; 92:2712-2718.
27. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors. Blood 2009; 113:775-783.
28. Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95:90-95.
29. Vahdat L, Maslak P, Miller WH, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84:3843-3849.
30. Navarro WH. Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 2003; 31:961-966.
31. Sekeres MA, Peterson B, Dodge RK, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood 2004; 103:4036-4042.